News

Tue, 2015-03-31
Dyax Announces Positive Results from Phase 1b Clinical Trial of DX-2930

Dyax Corp. has announced positive safety, pharmacokinetic, biomarker, and efficacy results from the Phase 1b clinical study of their investigational product, DX-2930. Discovered by Dyax, DX-2930 is a fully human monoclonal antibody inhibitor of plasma kallikrein being developed for the prevention of HAE attacks.

Fri, 2015-03-27
New hae day :-) website

Today HAEi has launched a new hae day :-) website - a forum dedicated to the global HAE awareness day.

Among many other things the website contains a number of case stories, shared by patients in order to help raise awareness of the effects of HAE on the everyday lives of people around the world. Also, the website contains an awareness campaign under the heading ‘Cover the World with Smiles’. It is the aim to literally cover the map on the website with smiles from patients and other supporters from all over the world.

Thu, 2015-03-19
Nominations to Pharming's Board Of Supervisory Directors

Pharming Group N.V. has nominated Paul Jai Sekhri and Jan Hendrik Egberts as members of the Board of Supervisory Directors. The nominations will be subject to shareholders’ approval at the upcoming Annual General Meeting of Shareholders, which will take place on 30 April 2015.

Fri, 2015-03-06
OPuS-2 study now enrolling patients

OPuS-2 is an 12 week study of BCX4161, an oral kallikrein inhibitor being studied for prevention of HAE attacks in patients with Type I and II HAE. This study is currently open to enrolling patients in the US, UK, and Germany, with planned clinical trial locations in Belgium, Canada, Hungary, Italy and France.

If you are interested in learning more about the study, please see https://clinicaltrials.gov/ct2/show/NCT02303626?term=BCX4161&rank=3 and contact HAEi or your country’s HAE patient organization representative. (Source BioCryst Pharmaceuticals Inc.)

Thu, 2015-03-05
Pharming Reports On Preliminary Financial Results 2014

Pharming Group N.V. has published its preliminary (unaudited) financial results for the year ended 31 December 2014.

From the financial highlights:

  • Revenues from operations increased to 21.2 million EUR (2013: 6.8 million EUR) as a result of higher license fees, including the receipt of a 20.0 million USD (16 million EUR) milestone from US partner Salix Pharmaceuticals, Inc. and increased product sales to 3.0 million EUR (2013: 0.9 million EUR) as a result of increased sales in the EU and initial sales in the US of 0.3 million EUR.

Teaser 4, 2nd row left, in news section

United We Stand Strong!

HAEi cares about you. We encourage patients to get organized - because "United We Stand Strong".

HAE International - Thumb 7HAE International - Thumb 7Become a National Member Organization (NMO). We are here to help you in founding a National Member Organization. Follow our step-by-step model. It doesn't have to be a difficult task creating the best foundation for patients in your country. Contact us for more information here


HAE International - Thumb 4HAE International - Thumb 4

Starting a National Patient Group (NPG). If you are interested in doing more around HAE - but don't feel that starting a full NMO is the right option here and now. You should maybe consider becoming a contact patient (NPG) for your country. Contact us here

Both NMO's and NPG's enjoy free membership of HAEi. Also we can help you host your country specific website under the global umbrella of HAEi.

Events

Thu, 2015-05-28 13:00 - Sun, 2015-05-31 14:00

9th C1 Inhibitor Deficiency Workshop

Venue: Danubius Thermal Hotel Margitsziget, Margitsziget, 1133 Budapest, Hungary
Language: English

It is our great pleasure to invite you to the 9th C1-INH Deficiency Workshop. This event has a history of many years, as well as its nature and objectives are familiar to many of us. Nevertheless, given the continued interest from first-time attendees, we would like to introduce the Workshop for them in brief, as follows.

This conference focuses on bradykinin-mediated angioedemas, and particularly on the types resulting from C1-inhibitor deficiency. The topics of this four-day long event cover a wide range of subjects.

Read more about the workshop here.

..continue
Fri, 2015-02-20 10:00 - Tue, 2015-02-24 16:00

AAAAI - Annual Meeting 2015

Venue: Houston, TX, United States of America
Language: English

Mark your calendars and head to Houston, Texas for the premier event in allergy/immunology. You will be able to earn CME/CE, learn about cutting-edge research and enrich your networking connections at the 2015 AAAAI Annual Meeting, February 20-24.

For more information please visit: AAAAI 2015
..continue

Homepage Teaser 6, 2nd row right

HAE Global Community

Be part of the HAEi Community

HAEi is here to help you. Therefore we have created the HAEi Community that gives you all the bells and whistles you know from other social media (such as Facebook) and even a very sophisticated Forum, where you can discuss with fellow HAE patients and care givers. The only difference is - that here your information stays safe - and will only be shared with other HAE patients and care givers. If you are a HAE patient or directly related to a HAE patient we urge you to register today - and become an important member of our community

Help yourself and stay updated by registering already today - then you will be the first to know.....

Do you have Questions?
You can find answers on our FAQ-Page or
send us an e-mail to: info@haei.org
or go to the contact form page


Experiencing browser problems?

Our website is working properly on most web browsers. However, we know that the site will not perform correctly on Microsoft Internet Explorer version 6 and earlier! So if you are using Internet Explorer from Microsoft please ensure that you have version 7 or higher!


See the video from the 2012 HAE Global Conference in Copenhagen

Click here


HAEDAYHAEDAYLook out for next hae day :-) on 16 May 2014


www.haeday.org